<DOC>
	<DOCNO>NCT00345293</DOCNO>
	<brief_summary>The purpose study assess safety activity DC/PC3 , dendritic cell vaccine use immunotherapy prostate cancer . The vaccine make participant ' immune cell obtain blood donation . Dendritic cell know activate immune cell T cell , able mount attack cancer cell . The dendritic cell vaccine administer injection every 2 week course 2 month .</brief_summary>
	<brief_title>Dendritic Cell Vaccine Study ( DC/PC3 ) Prostate Cancer</brief_title>
	<detailed_description>See Brief Summary .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Prostate cancer Rising prostate specific antigen ( PSA , 3 value , measure least 2 week apart ) post initial therapy ( ie , radiation , prostatectomy ) human leukocyte antigen A2.1 ( HLAA2.1 ) central nervous system metastasis History autoimmune disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>